Diabetes Drug Actos: Bladder Cancer Risk?
November 21 2010, 3:35 am
http://diabetes.webmd.com/The FDA has launched a safety review of the diabetes drug Actos. An ongoing 10-year study suggests that long-term Actos use may increase bladder cancer risk.
Actos Med | Fda Actos
November 21 2010, 3:35 am
http://ava-game.com/actos for pcos actos online pharmacy actos de amor actos discount actos vs glipizide fdisk actok actos met actos heart disease actos takeda lactose intolerance actos banned actos therapeutic class actos bladder cancer actos 45 ...
Actos Bladder Cancer Risk Being Reviewed by FDA - AboutLawsuits.com
November 21 2010, 3:35 am
http://www.aboutlawsuits.com/Federal drug reviewers are investigating whether the side effects of Actos, a diabetes drug that is part of the same class of medications as Avandia, may be.
Diabetes Alert: Actos Linked To Bladder Cancer
November 21 2010, 3:35 am
http://fuiszreport.typepad.com/After Avandia, it is now the turn of Actos to be linked to life-threatening conditions. On September 17 the United States Food and Drug Administration […] Original: Actos - WordPress.com Search.
foodconsumer.org - FDA: Diabetes drug Actos linked to bladder cancer
November 21 2010, 3:35 am
http://www.foodconsumer.org/The United States Food and Drug Administration announced Sept 17 it is reviewing the link between use of the diabetes drug Actos or pioglitazone and elevated risk of bladder cancer among patients with type 2 diabetes mellitus who were ...
Preliminary Evidence Links Diabetes Drug Actos to Bladder Cancer
November 21 2010, 3:35 am
http://www.emaxhealth.com/The US Food and Drug Administration (FDA) has announced that it will investigate preliminary epidemiological evidence that suggests a link between the...
FDA reviews potential bladder cancer risk with Actos - MPR
November 21 2010, 3:35 am
http://www.empr.com/Takeda had conducted a planned analysis of the study data at the five-year mark, and submitted their results to FDA.
Article FDA reviews Actos over bladder cancer link
November 21 2010, 3:35 am
http://www.pharmatimes.com/The US Food and Drug Administration is reviewing Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of the $4 billion-a-year ...
